| Remdesivir in treatment of COVID-19: A systematic benefit–risk assessment M Davies, V Osborne, S Lane, D Roy, S Dhanda, A Evans, S Shakir Drug safety 43, 645-656, 2020 | 84 | 2020 |
| Lopinavir-ritonavir in the treatment of COVID-19: a dynamic systematic benefit-risk assessment V Osborne, M Davies, S Lane, A Evans, J Denyer, S Dhanda, D Roy, ... Drug safety 43 (8), 809-821, 2020 | 75 | 2020 |
| Non-medical opioid use in youth: Gender differences in risk factors and prevalence V Osborne, M Serdarevic, H Crooke, C Striley, LB Cottler Addictive behaviors 72, 114-119, 2017 | 67 | 2017 |
| Incidence of venous thromboembolism in users of strontium ranelate V Osborne, D Layton, M Perrio, L Wilton, SAW Shakir Drug safety 33 (7), 579-591, 2010 | 45 | 2010 |
| Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? S Dhanda, V Osborne, E Lynn, S Shakir BMJ evidence-based medicine, 2020 | 35 | 2020 |
| The association between insomnia and prescription opioid use: results from a community sample in Northeast Florida M Serdarevic, V Osborne, CW Striley, LB Cottler Sleep health 3 (5), 368-372, 2017 | 34 | 2017 |
| Reported adverse events with painkillers: data mining of the US Food And Drug Administration adverse events reporting system J Min, V Osborne, A Kowalski, M Prosperi Drug safety 41 (3), 313-320, 2018 | 32 | 2018 |
| Sex differences in patterns of prescription opioid non-medical use among 10–18 year olds in the US V Osborne, CW Striley, SJ Nixon, AG Winterstein, LB Cottler Addictive behaviors 89, 163-171, 2019 | 30 | 2019 |
| Power of the peer and parent: gender differences, norms, and nonmedical prescription opioid use among adolescents in South Central Kentucky KL Egan, E Gregory, VL Osborne, LB Cottler Prevention science 20 (5), 665-673, 2019 | 24 | 2019 |
| Safety of intranasal quadrivalent live attenuated influenza vaccine (QLAIV) in children and adolescents: a pilot prospective cohort study in England R McNaughton, E Lynn, V Osborne, A Coughtrie, D Layton, S Shakir Drug safety 39 (4), 323-333, 2016 | 24 | 2016 |
| Utilisation of extended release quetiapine (Seroquel XL™): Results from an observational cohort study in England V Osborne, M Davies, D Layton, SAW Shakir European Psychiatry 33 (1), 61-67, 2016 | 24 | 2016 |
| A longitudinal analysis of the substance abuse, violence, and HIV/AIDS (SAVA) syndemic among women in the criminal justice system AA Jones, T Gerke, CW Striley, V Osborne, N Whitehead, LB Cottler Journal of psychoactive drugs 51 (1), 58-67, 2019 | 21 | 2019 |
| Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management V Osborne, M Davies, D Roy, F Tescione, SAW Shakir BMJ evidence-based medicine 25 (6), 199-205, 2020 | 12 | 2020 |
| Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management D Layton, V Osborne, M Al-Shukri, SAW Shakir Drug safety 37 (8), 639-650, 2014 | 12 | 2014 |
| What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19 V Osborne, SAW Shakir Frontiers in Pharmacology 11, 2020 | 11 | 2020 |
| Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care … A Evans, M Davies, V Osborne, D Roy, S Shakir BMJ open 10 (11), e038102, 2020 | 10 | 2020 |
| Utilization of fentanyl buccal tablets in England: Exploring off‐label use reported in a cohort study V Osborne, D Layton, C Fogg, M Al‐Shukri, SAW Shakir European Journal of Pain 18 (4), 506-512, 2014 | 10 | 2014 |
| Utilisation and safety of deferasirox: results from an observational cohort study in England V Osborne, M Davies, D Layton, SAW Shakir Drug safety 41 (3), 267-275, 2018 | 9 | 2018 |
| Age of First Use of Prescription Opioids and Prescription Opioid Non-Medical Use among Older Adolescents V Osborne, M Serdarevic, CW Striley, SJ Nixon, AG Winterstein, ... Substance Use & Misuse 55 (14), 2420-2427, 2020 | 8 | 2020 |
| Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data D Layton, VM Osborne, A Gilchrist, SAW Shakir Drug safety 34 (12), 1177-1189, 2011 | 7 | 2011 |
